Thomas Smith
Stock Analyst at Leerink Partners
(1.05)
# 3,427
Out of 4,810 analysts
71
Total ratings
29.03%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.46 | +115.98% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $2.02 | +346.65% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.12 | +525.00% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $5.11 | +467.51% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $11.97 | +225.81% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $2.17 | +1,098.16% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $0.86 | +1,066.32% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $6.06 | +230.03% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $605.38 | -28.14% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $41.31 | -12.85% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $0.83 | +743.58% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $15.47 | +35.79% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $12.80 | +251.56% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $6.20 | -3.23% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $4.64 | +29.45% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.99 | +406.07% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $36.77 | -53.77% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $18.37 | +248.39% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $16.68 | +319.78% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $6.05 | +379.34% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $3.01 | +763.79% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $13 → $12 | $0.32 | +3,615.17% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $23.11 | -48.07% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.69 | +171.37% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $2.57 | +15,464.20% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $13.09 | +511.15% | 2 | Dec 8, 2020 |
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.46
Upside: +115.98%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $2.02
Upside: +346.65%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.12
Upside: +525.00%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $5.11
Upside: +467.51%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $11.97
Upside: +225.81%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $2.17
Upside: +1,098.16%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $0.86
Upside: +1,066.32%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $6.06
Upside: +230.03%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $605.38
Upside: -28.14%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $41.31
Upside: -12.85%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $0.83
Upside: +743.58%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $15.47
Upside: +35.79%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $12.80
Upside: +251.56%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $6.20
Upside: -3.23%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $4.64
Upside: +29.45%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.99
Upside: +406.07%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $36.77
Upside: -53.77%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $18.37
Upside: +248.39%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $16.68
Upside: +319.78%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $6.05
Upside: +379.34%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $3.01
Upside: +763.79%
May 12, 2022
Maintains: Market Perform
Price Target: $13 → $12
Current: $0.32
Upside: +3,615.17%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $23.11
Upside: -48.07%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.69
Upside: +171.37%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $2.57
Upside: +15,464.20%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $13.09
Upside: +511.15%